Home › Colon Cancer › Illinois › Bloomington
Colon Cancer clinical trials in Bloomington, IL
4 studies for Colon Cancer are looking for participants at sites in and around Bloomington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RecruitingPhase 2/3
- Illinois CancerCare-Bloomington, Bloomington
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
RecruitingHealthy volunteers welcome
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi away
- Carle Cancer Institute Normal, Normal · 2 mi away
Family Communications After Genetic Testing
RecruitingHealthy volunteers welcome
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi away
- Carle Cancer Institute Normal, Normal · 2 mi away
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Illinois CancerCare - Bloomington, Bloomington
Colon Cancer trials in other cities
- New York City, NY24 studies
- Boston, MA23 studies
- Houston, TX20 studies
- Nashville, TN17 studies
- Los Angeles, CA17 studies
- Chicago, IL16 studies
- Arlington, VA15 studies
- Seattle, WA15 studies
- Tampa, FL15 studies
- Baltimore, MD14 studies
- St. Louis, MO14 studies
- San Antonio, TX14 studies
Other studies in Bloomington
- Non-Small Cell Lung Cancer12 studies
- Lung Cancer10 studies
- Prostate Cancer7 studies
- Colorectal Cancer7 studies
- Breast Cancer5 studies
- Melanoma5 studies
- Pancreatic Cancer5 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Bladder Cancer4 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
- Acute Myeloid Leukemia4 studies
- Hypopharyngeal Cancer4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.